CheckMate 77T
Descrição
Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)
AACR: Bristol Myers details Opdivo's presurgery lung cancer win
CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
Revisiting neoadjuvant therapy in non-small-cell lung cancer - The
Pre- and Postsurgical Immunotherapy Improves Outcomes in Operable
The Era of Neoadjuvant Immunotherapy in Resectable Non–Small Cell
Sergio Vázquez on X: Another player in the perioperative game
CheckMate-77T: Perioperative nivolumab benefit for NSCLC - ecancer
CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC
CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC
de
por adulto (o preço varia de acordo com o tamanho do grupo)
